This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mary, V. Articles by Stutzmann, J.-M. Search for Related Content PubMed PubMed Citation Articles by Mary, V. Articles by Stutzmann, J.-M. Pubmed/NCBI databases Substance via MeSH Hazardous Substances DB HEPARIN Medline Plus Health Information Stroke Related Collections Neuroprotectors

(Stroke. 2001;32:993.)
© 2001 American Heart Association, Inc.

Original Contributions

Enoxaparin in Experimental Stroke

Neuroprotection and Therapeutic Window of Opportunity

Véronique Mary, PharmD; Florence Wahl, PhD; André Uzan, PharmD Jean-Marie Stutzmann, PhD

From CNS Research, Aventis Pharma, CRVA, Vitry-sur-seine, France.

Correspondence to Dr Véronique Mary, CNS Research, Aventis Pharma, CRVA, Zone D, 13 quai Jules Guesde, 94403 Vitry-sur-seine, France. E-mail veronique.mary{at}aventis.com

Background and Purpose—Heparin and heparinoids have long been proposed for stroke treatment. This study investigates the effect of enoxaparin (Lovenox, Clexane), a low-molecular-weight heparin, on functional outcome (neuroscore) and lesion size in stroke models with reversible and irreversible cerebral ischemia using middle cerebral artery occlusion (MCAO) in the rat.

Methods—Ischemia was induced in rats by transient occlusion for 2 hours or by permanent electrocoagulation of the left MCA. Forty-eight hours after ischemia, neurological deficit was evaluated by scoring sensorimotor functions and ischemic damage was quantified by histological evaluation of lesion volumes.

Results—After transient MCAO, enoxaparin at 2x1.5 mg/kg IV (2 and 24 hours after insult) significantly reduced lesion size by 30% (P<0.05) and improved neuroscore (P<0.01). This significant effect on lesion size and neuroscore was still evident when treatment was started 5 hours after insult. Administered under the same protocol with a 5 hours delay post permanent MCAO, enoxaparin reduced lesion size by 49% (P<0.05) and improved neuroscore (P<0.01).

Conclusions—This study indicates that standard nonhemorrhagic doses of enoxaparin reduce ischemic damage with a wide therapeutic window. In addition to its anticoagulant properties, other properties of enoxaparin could act in synergy to explain its neuroprotective profile in ischemia. Thus clinical application of enoxaparin treatment in stroke warrants serious consideration.

Key Words: cerebral ischemia, focal • heparin • neuroprotection • thrombolytic therapy • rats

This article has been cited by other articles:

				O. Cuomo, G. Pignataro, R. Gala, A. Scorziello, E. Gravino, O. Piazza, R. Tufano, G. Di Renzo, and L. Annunziato Antithrombin Reduces Ischemic Volume, Ameliorates Neurologic Deficits, and Prolongs Animal Survival in Both Transient and Permanent Focal Ischemia Stroke, December 1, 2007; 38(12): 3272 - 3279. [Abstract] [Full Text] [PDF]

				T.-S. Tang, E. Slow, V. Lupu, I. G. Stavrovskaya, M. Sugimori, R. Llinas, B. S. Kristal, M. R. Hayden, and I. Bezprozvanny Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease PNAS, February 15, 2005; 102(7): 2602 - 2607. [Abstract] [Full Text] [PDF]

				R. Strater, K. Kurnik, C. Heller, R. Schobess, P. Luigs, and U. Nowak-Gottl Aspirin Versus Low-Dose Low-Molecular-Weight Heparin: Antithrombotic Therapy in Pediatric Ischemic Stroke Patients: A Prospective Follow-Up Study Stroke, November 1, 2001; 32(11): 2554 - 2558. [Abstract] [Full Text] [PDF]